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Stem cellis a progressive neurodegenerative disorder in which the degeneration of
dopaminergic neurons projecting from the substantia nigra to the striatum is a key pathological feature of
the disease. Although pharmacological dopamine replacement is generally very effective in early disease, it is
only a symptomatic therapy and can have signiﬁcant side effects with long term use. One of the key strategies
in a more restorative approach to PD therapy involves replacement of this degenerating nigro-striatal
dopaminergic network with cells and several possible cell sources are being explored. While much
experience and some success have been gained with fetal ventral mesencephalic (FVM) tissue transplants,
the rapidly advancing stem cell ﬁeld is providing attractive alternative options which circumvent many of the
ethical and practical problems inherent in trials with FVM tissue. Of these embryonic stem cells and induced
pluripotent stem cells seem the most promising. However further development and optimisation of the
safety and efﬁcacy of the techniques involved in generating and manipulating these, as well as other, cell
sources will be essential before any further clinical trials are carried out.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionParkinson's disease (PD) is a common neurodegenerative disease
affecting approximately 1% of people over 65 years of age. It is
characterised clinically by the development of bradykinesia, rigidity
and a resting tremor, which has been attributed in part to the
progressive degeneration of the dopaminergic input from the
substantia nigra to the striatum. The cause for this progressive loss
of nigrostriatal dopaminergic neurones is not entirely understood, but
it is associated with the presence of alpha-synuclein positive Lewy
bodies, in the remaining substantia nigra pars compacta neurones
(SNc) at post-mortem. However, Lewy bodies are also found in many
other parts of the brain (including other subcortical and brainstem
nuclei as well as the cortex) and this diffuse pathology underlies the
other non-motor features of PD such as cognitive, sleep and affective
problems as well as autonomic dysfunction, which are found in many
PD patients. Indeed it has even been proposed that this non-nigral
pathology dominates the very early and late stages of disease [1–3].
Nevertheless, despite this non-nigral, non-dopaminergic patho-
logy, the principal feature of the disease remains the progressive loss
of dopamine in the striatum, which can be treated successfully with a
range of symptomatic dopaminergic drug therapies. Thus both
levodopa and dopamine agonists can signiﬁcantly help many of the
features of PD, particularly in the early stages of the disease. However
with time, the disease progresses and this coupled to the long-termRepair, Forvie Site, Robinson
ll rights reserved.use of dopaminergic drug therapies produces a range of problems
including the development of drug-inducedmotor complications such
as “on–off” ﬂuctuations and levodopa-induced dyskinesias (LID). At
this stage of the disease simple drug therapies become increasingly
disappointing in terms of a reliable therapeutic beneﬁt and thus other
approaches are sought including more invasive ways of delivering
more continuous dopaminergic therapy such as apomorphine pumps
and DuoDopa®, as well as neurosurgical interventions such as deep
brain stimulation which typically, but not exclusively, targets the
subthalamic nucleus.
These latter therapies can be very effective, but only ever treat the
symptoms without any attempt to repair the underlying diseased
network. Thus these treatments also start to fail, in part because of
the progressive nature of the non-nigral, non-motor aspects of PD
and in part because of the continued loss of nigral dopaminergic
neurones. Therefore, while a more complete understanding of
disease pathogenesis may enable us to better treat all aspects of PD,
more restorative approaches that involve repairing the dopaminergic
nigrostriatal tract (including cell replacement, neurotrophic support
and pharmacological and gene therapies) may also prove very useful
(see Table 1). It is this latter area that we will be concentrating on in
this review, as we discuss the different approaches using cell
therapies in PD and their clinical efﬁcacy to date.
Cell therapies in PD have been a major research interest for the last
30 years with the main focus being on using them for replacement of
the degenerating, and lost, dopaminergic neuronal innervation of the
striatum from the nigra. This review will discuss the different sources
for dopaminergic cell replacement therapy in PD, with a particular
emphasis on fetal ventral mesencephalic tissue and stem cell sources
Table 1
Potential disease-modifying or neuroprotective/neurorestorative strategies for PD
Pharmacological The use of drugs to slow down the disease process;
neuroprotective agents.
eg. Possibly dopamine agonists — ropinirole (REAL-PET
study [218]); pramipexole (CALM-PD study [219,220]);
rasagiline (TEMPO study [221]; ADAGIO study, Press
Release 2008 [236]).
Direct infusion
of neurotrophic factors
GDNF to rescue dopaminergic neurons [222,223]
Cell therapies Cell replacement of lost dopaminergic neurons.
eg. Transplantation of fetal ventral mesencephalon
[48,58,62].
Cells engineered to deliver growth factor support to help
rescue dopaminergic neurons.
eg. Implanting GDNF secreting cell lines [224,225]
Gene therapya Providing neurotrophic/supportive factors to dopaminergic
neurons [226–229,232]
eg. Ceregene neurturin trial [230]
a This approach has also been employed to replace neurotransmitters within the
basal ganglia circuitry, which is not strictly a neuroprotective/neurorestorative
approach. This includes:
1) Providing better local delivery of dopamine. Tricistronic viral vector-mediated
transfer of genes involved in the dopaminergic synthetic pathway [231].
2) Increasing synthesis of GABA within the subthalamic nucleus. Transfer of adeno-
associated virus (AAV) borne glutamic acid decarboxylase (GAD) gene into the
subthalamic nucleus [233].
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of the striatum rather than reconstruction of the nigrostriatal
pathway. Obviously, cell therapies can be used to repair/restore
function through mechanisms other than simple cell replacement and
while this is not the subject of this review, it should be stressed that
cell therapies for PD may work by more than one pathway which are
all complementary in mediating repair (Table 1 and Fig. 1).Fig. 1. Drawing illustrating some of the potential ‘disease modifying’ or neuroprotective/neu
(S), putamen (P) and globus pallidus (GP) appear in red. (Adopted from illustration by MicA number of different types of ‘dopaminergic-like’ cell have been
considered for grafting in PD (see Fig. 2) and in this review we will be
concentrating on those which have shown the greatest clinical beneﬁt
(e.g fetal ventral mesencephalon (FVM)) and those with the greatest
promise (e.g.: embryonic stem cells (ESCs) and induced pluripotent
stem (iPS) Cells).
2. Autografts
The use of autografts has always been attractive for the treatment
of any disorder including Parkinson's disease because of the ease of
tissue collection without the ethical and immunological problems
inherent in allogenic and xenogenic tissue. It is therefore not
surprising that much of the early work on cell therapies for PD
concentrated on autologous cellular sources of dopamine, although
overall the results to date have been disappointing using tissue of this
type.
2.1. Adrenal medulla
Initial attempts at autologous cell transplantation in PD included
the use of adrenal medullary (AM) tissue, which secretes some
dopamine among other catecholamines. Early studies in animal
models of PD were very variable, but provided some evidence for
survival and functional efﬁcacy [4–6]. Despite uncertainties about the
mode of action of the AM grafts and the limited functional beneﬁts
experimentally, small open label clinical trials started in the early
1980s with all the inherent problems that exist when no placebo
group is used for comparison — a problem that has emerged many
times in this ﬁeld of brain repair. Nevertheless these early studies with
AM transplants produced some slight transient improvement for the
patients [7,8], while another group at around the same time reported
signiﬁcant motor and cognitive improvements using an openrorestorative strategies for PD. The substantia nigra (SN) appears in green. The striatum
k Cafferkey).
Fig 2. Figure illustrating some of the cell sources considered for dopaminergic cell replacement in Parkinson's disease.
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data from this study has been queried [11].
Subsequently, other studies showed a modest effect (an increase,
from 47.6% to 75% in time spent in the ‘on’ phase of L-dopa treatment)
for a limited period of time only, namely ∼18 months [12,13].
Furthermore, post-mortem studies showed poor survival of grafted
tissue [14,15] with a recent neuropathological study done 16 years
after an autologous adrenal medullary transplantation showing few
surviving chromogranin A positive cells and a complete absence of
cells staining for tyrosine hydroxylase (TH) (the key enzyme in
dopamine synthesis) at the graft site [16]. This patient had derived
some clinical beneﬁt from the graft for ∼4 years post transplantation.
In order to improve the survival of these AM transplants, co-grafts
of tissue secreting Nerve Growth Factor (NGF) were investigated. The
animal studies underpinning this approach involved co-grafting AM
with pre-transected peripheral nerve (a source of NGF) and showed
improvement in graft survival and functional recovery [17,18].
However clinical studies using a similar approach have reported
only modest improvements of Uniﬁed Parkinson's Disease Rating
Scale (UPDRS) scores in both ‘on’ and ‘off’ phases with an increased
proportion of time when the dopaminergic medication is working,
namely the ‘on’ phase [19,20], with a corresponding reduction in the
“off” phase. Clinical trials of direct NGF infusion to support AM
autografts have also been tried with some beneﬁt [21]. However the
high level of morbidity and mortality associated with the techniques
involved in the obtainment and transplantation of AM tissue are
signiﬁcant and currently outweigh the (at best) modest beneﬁts ofthese grafts. As a result there is little justiﬁcation to continue with AM
transplants for PD.
2.2. Sympathetic ganglion neurones
Sympathetic ganglion neurones have also been considered as a
source of cell replacement for PD as they express AADC and VMAT2,
(proteins involved in the production and transport of dopamine) in
culture [22] as well as following transplantation in a rat model of PD
[23]. Their action is thought to be mediated by their ability to convert
and store dopamine found in the extracellular space. In clinical studies
sympathetic ganglion tissue has been harvested from the cervical
[24–26] or thoracic [22,23] sympathetic trunk and transplanted into
the striatum of patients with PD. Approximately half the patients
having such grafts experienced reduced ‘off’ time and increased ‘on’
time with an overall improvement in bradykinesia and gait in some,
but no signiﬁcant change in UPDRS scores. These limited clinical
beneﬁts and the invasive techniques and associated morbidity of the
procedure involved in obtaining the donor tissue make this a
relatively impractical option for clinical use in patients with PD.
2.3. Carotid body
The cells of the carotid body are known to be chemosensitive and
secrete dopamine and divide in response to hypoxic stimuli [27,28].
These properties have led to an exploration of their use in
dopaminergic cell replacement for PD and animal studies in rodents
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recovery following intra-striatal transplantation of carotid body cell
aggregates [28–30]. This led to a clinical study, in which 13 patients
aged 43–61 years with advanced PD underwent bilateral carotid body
transplants into the striatum [31]. Improvement in the UPDRS motor
score at 1 year post transplantation was the primary outcome
measure, which most patients achieved with a reduction in their
UPDRS ‘off’ score of between 13% and 52%. Of the 6 patients assessed at
3 years post transplant, the improvement was maintained in 3 and
this appeared to correlate with milder baseline disease severity and
the absence of ﬁbrotic atrophy within the carotid body [32].
There was, however, no increase in ﬂuorodopa (F-dopa) uptake – a
measure of presynaptic dopaminergic nerve terminals – in the
transplanted striatum on Positron Emission Tomography (PET)
imaging and thus the reason for the motor improvement was not
clear. Surviving numbers of dopaminergic neurons in the transplants
were only ∼10% of that seen in the successful fetal ventral
mesencephalic allograft recipients (see below) and so the authors
suggest that the therapeutic beneﬁt of carotid body cell transplants
may relatemore to the release of trophic factors rather than dopamine
release. However, PET scanning data from successful trophic factor
(GDNF) infusion studies in PD have shown increases in striatal F-dopa
uptake in response to trophic factor infusion [33] so that if this were
the explanation for the success of the carotid body transplants, one
would still expect to see a change in PET F-dopa signal.
3. Allografts
3.1. Retinal pigment epithelium
The cells of the retinal pigmentary epithelium (RPE) act as support
cells in the retina and produce L-dopa as part of their melanin
synthetic pathway. They have also been shown to have neurotrophic
effects on rat striatal and mesencephalic neurones in vitro [34] and
have been investigated as a source of dopaminergic cells for
transplantation in PD. The attachment of the RPE cells to microcarriers
made of gelatin seems to increase their survival on grafting and
studies in rat and primate PD models have shown improvements in
motor symptoms and F-dopa PET imaging following their transplan-
tation [35,36]. This led to a clinical open label trial involving human
RPE cells attached to microcarriers (Spheramine™) which were
transplanted unilaterally into the putamen of 6 patients with
advanced PD. This brought about an average improvement in the
‘off’ UPDRS motor score of ∼48% at 1 year. Following this a double-
blind placebo controlled study using Spheramine™ was commenced.
Initial analyses of results, however, have not detected any signiﬁcant
differences between the Spheramine and sham surgery arms of the
study after 12months of follow up and the future potential of RPE cells
as a source for cell replacement therapy in PD is still unclear ([234]).
3.2. Fetal ventral mesencephalic transplants
3.2.1. Animal studies
The very ﬁrst successful attempts at fetal dopaminergic cell
transplantation were reported by two groups in 1979. The procedure
involved the allogenic transplantation of fetal ventral mesencephalon
(VM) tissue into the rat 6-OHDA model of PD. Perlow et al. placed the
grafts into the lateral ventricle [37], while a dorsal cortical cavity was
used by Björklund and Stenevi for the placement of their grafts [38]. In
both studies, functional recovery was described on simplemotor tasks
and subsequent studies conﬁrmed this and showed that there was
graft survival, dopaminergic ﬁbre outgrowth and synapse formation
seen on histological analysis [39]. While improvements were seen
when the tissue was placed striatally, attempts to place grafts in the
substantia nigra, the site of dopaminergic neuronal cell body
degeneration, showed survival of cells, but they did not seem toextend axons to the striatum and thus produce functional improve-
ments [40]. This dependence on the striatal location of the graft for
functional beneﬁts [41], which has become the main site of
dopaminergic graft implantation, showed some topographical speci-
ﬁcity with more ventrally placed grafts in the striatum having greater
effects on more complex nonmotor tasks. [41,42]. The beneﬁts were
also dependent on the age of the donor embryo, such that harvesting
the tissue at the time of normal dopaminergic nigral developmentwas
critical (reviewed in [43]). These rodent studies were then extended
to non-human primates [44–47], where it was shown that the same
principles apply.
These initial allogenic animal studies led onto work with human
fetal ventral mesencephalon (VM) transplants in rat PDmodels. These
studies demonstrated that human fetal VM tissue transplanted into
the 6-OHDA rat striatum could survive, integrate, form dopaminergic
connections and produce functional improvement [48] and were best
seen in immunosuppressed rats receiving grafts from younger, 6-
8 week old, fetuses. These animal studies paved the way for the
translation of this experimental therapy to patients with PD, although
even at this stage it was clear that striatally placed transplants of fetal
VM could not improve all the deﬁcits seen in this simple animal model
of PD. As such it would be naive to expect such transplants to reverse
all aspects of PD in the more complex situation of patients and this
needs to be borne in mind when interpreting any clinical trials using
this approach.
3.2.2. Clinical studies
3.2.2.1. Open-label trials. The ﬁrst clinical trials were carried out in
the 1980s in Mexico [49] and Sweden [50] with 2 PD patients in each
trial. The studies used VM tissue from 12 to 14 week and 8 to 10 week
old embryos respectively, which was transplanted into the striatum
with minimal clinical improvement, at least in the patients from
Sweden. However, by reﬁning the techniques, several subsequent
open-label clinical studies have shown signiﬁcant improvements in a
number of parameters, including the UPDRS, Activities of Daily Living
(ADL) scale, health related quality of life and levodopa requirements.
[51–57]. These clinical improvements have been sustained and
associated with increased ﬂuorodopa (F-dopa) uptake on PET scans,
as well as regulated dopamine release and activation of motor cortical
areas [58,59]. Furthermore, early (18 month) post-mortem patholo-
gical studies also showed the survival of grafted fetal VM dopaminer-
gic neurones (∼ between 81,905 and 135,673 TH+ neurons), with
graft-mediated striatal reinnervation [57,60]. Therefore the initial
open label clinical studies demonstrated that fetal VM allografts could
survive in patients with PD, become functionally integrated and
produce sustained clinical beneﬁts. However, the results were variable
and one of the challenges was to explain this variability and how it
could be minimised — an anxiety that became more of an issue with
the publication of 2 double blind, placebo-controlled trials of fetal VM
transplantation in PD.
3.2.2.2. Double-blind placebo controlled trials. With encouragement
from the initial open label results and the argument for the need to
properly support the actual efﬁcacy of the procedure, two double-
blind placebo controlled trials of fetal VM transplantation in PD were
funded by the National Institutes of Health (NIH), USA in the 1990s.
The ﬁrst trial was published in 2001 by Freed et al. It involved 40
patients with PD aged between 34 and 75 years and mean disease
duration of 14 years [61]. Patients were randomly assigned to receive a
transplant or imitation, sham surgery. VM tissue was obtained from
aborted 7–8week old embryos, cultured in F12medium containing 5%
human placental serum for up to 4 weeks prior to transplantation and
specially prepared into strands of tissue. The transplants took place
under local anaesthetic with the patient awake and involved
stereotactic neurosurgical techniques. Tissue from two embryos was
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ssion was used. The control patients received a sham surgical
procedure involving burr holes with no penetration of the dura.
The primary outcome, a subjective global rating of clinical improve-
ment at 1 year post transplant, showed no signiﬁcant improvement in
the transplant compared to the placebo group. However signiﬁcant
improvements were seen in the ‘off’ medication UPDRS total and
motor scores in transplant patients below 60 years of age.
Subsequent analysis however suggested that the main determinant
of this correlation was the preoperative levodopa responsiveness
rather than the age of the patient, as even older patients with good
preoperative levodopa responsiveness showed similar improve-
ments [62]. The main motor improvements were in rigidity and in
the younger patients, bradykinesia, while tremor showed no
response. Despite the modest and variable clinical beneﬁts, PET
scanning showed signiﬁcant increases in F-dopa uptake in the
putamen of the transplant group compared to placebo and post-
mortem examinations showed dopaminergic neuronal survival and
ﬁbre outgrowth in the grafts. However, the number of surviving
cells was less than that reported by others in patients with good
clinical responses to their transplants (eg — ∼11,592–20,188 at
7 months and ∼2060–22,760 at 3 years) [61]. However, of concern in
this trial was the ﬁrst clear description of the development of
signiﬁcant graft induced dyskinesias (GID) in 15% of transplanted
patients more than 1 year post transplant: dyskinesias that occurred
in the absence of medication, but presence of the graft. Several of
these patients required further surgical intervention to relieve them
of these GIDs [63].
The reason for this negative outcome and the induction of GIDs
was, and is still, unknown, but various factors may be critical including
the following. The amount of tissue grafted was less than other more
successful transplant trials and this was borne out by the post-mortem
data. The neurosurgical approach used a different trajectory to target
the striatal complex, which may have led to problems with
dopaminergic cell distribution; a ﬁnding that gains some credence
from the follow up PET study of Ma et al. showing dopaminergic hot
spots in patients developing GID [64]. The absence of immunosup-
pressive therapymay have compromised dopaminergic cell survival in
the graft as may the storage of the tissue for up to 1 month prior to
implantation. For these reasons it could be argued that the trial
produced negative results with side effects for methodological
reasons. However the second study by Olanow et al, published in
2003 tended to support, rather than refute, this trial result.
This second NIH sponsored study [65] involved 34 patients with
advanced PD, aged between 30 and 75 years. Patients were
randomised to receive bilateral transplantation with either one or
four donors per side or a ‘placebo’/sham transplant procedure. Solid
VM tissue was obtained from 6 to 9 week fetuses, stored in a
hibernation medium for 2 days prior to transplantation. The surgery
was performed under general anaesthesia using a 2 stage procedure
separated by a week, with the tissue from one or four embryos being
transplanted into the putamen bilaterally. All patients received
immunosuppression with cyclosporine 2 weeks preoperatively and
up to 6months postoperatively. Sham surgery consisted of partial burr
holes only with no breach of the dura.
The primary outcome measure was a change in the motor
component of the UPDRS in the practically deﬁned ‘off’ state, between
the baseline and the ﬁnal 24 month visit. Once again, no signiﬁcant
overall treatment effect was observed, although there was a tendency
towards an improvedmotor score in the 4 donor group. Therewas also
no difference between groups in terms of the change in percentage
‘on’ timewithout dyskinesias and in required L-dopa dose equivalents.
However, stratiﬁcation based on disease severity displayed that four
donor transplant patients with less severe disease (UPDRS≤49 at
baseline) did show signiﬁcant improvement in their UPDRS motor
scores. Also patients in the one- and four-donor transplant groupsshowed signiﬁcant motor improvement compared to placebo at 6 and
9months post transplant, but deteriorated thereafter, perhaps relating
to discontinuation of the immunosuppressive therapy at this time
point. This initial improvement was similar to that reported for
previous open label studies [51,66,67].
PET scanning showed signiﬁcant bilateral increases in striatal F-
dopa uptake in both transplant groups compared to placebo with the
four donor group showing the greatest increase. Post mortem
examination also showed good survival of dopamine neurones with
relatively seamless reinnervation of the striatum, again with the four
donor group showing the better results. However, as in the Freed et al.
study there was, worryingly, the development of signiﬁcant ‘off-
medication’ graft induced dyskinesias (GID) in 56.5% of the grafted
patients 6–12 months after transplantation. These dyskinesias con-
sisted of stereotypic, rhythmic movements of one or both lower
extremities, with three patients requiring further surgical interven-
tion to reduce their severity.
Thus, the results from these two double-blind placebo controlled
trials raised serious concerns about the utility and safety of FVM
transplants in patients with PD. The main concerns related to the
modest (non-statistically signiﬁcant) efﬁcacy of the transplants
compared to previous open-label trials and to the development, in a
signiﬁcant number of patients, of GID. The reasons for these negative
outcomes and the development of GID remain unresolved, but may
relate to patient selection, graft tissue preparation and placement and
the extent of immunosuppression. We will now deal with each of
these items in turn.
3.2.2.2.1. Patient selection. The evidence that this may be an
important factor comes from the observation that the best results in
the double blind placebo controlled trials were seen in patients with
less severe disease (UPDRSb49 at baseline) and best preoperative
response to levodopa [62]. There is also some evidence that older
patients do less well [61].
3.2.2.2.2. Tissue preparation and placement. Factors such as the
number and age of embryos used, coupled to the methods of storage
and preparation and the techniques used in graft placement, may all
have affected the survival and functional integration of donor
dopaminergic neurones. Thus in the Freed et al. study the methods
adopted involved less tissue, stored for longer times, delivered by a
transfrontal approach, while Olanow et al. used tissue pieces, stored
for short periods of time. Many studies have shown that a variety of
factors in the tissue preparation process are critical for optimisation of
dopaminergic cell survival in transplants and some of the factors in
the tissue preparation protocols adopted by the trials may have had a
deleterious effect on dopaminergic cell survival post transplantation
[68,69]. Furthermore there is recent evidence for the emergence of PD
like pathology in long term transplants of FVM and how this relates to
the preparation and engraftment of the tissue remains unresolved
(see below).
3.2.2.2.3. Immunosuppression. Although the brain is considered
to be an immunologically privileged site, the host immune system can
respond to the grafts, especially if they are not well matched from an
HLA perspective to the host. This may relate to the drainage of antigen
from the grafted cells out of the central nervous system into the deep
cervical lymph nodes, the presence of activated T cells patrolling the
central nervous system and the breach of the blood–brain barrier (one
of the main factors contributing to the immune privilege) by the
grafting procedure [70]. In Olanow et al.'s placebo controlled trial
which involved immunosuppression with cyclosporine for 6 months,
there was a deterioration in clinical response 6–9 months after
grafting, with post-mortem tissue evidence for activated microglia
and immune reactivity (CD45) in and around the graft deposits [65].
All of this may have compromised dopaminergic cell survival in the
transplant.
3.2.2.2.4. Graft induced dyskinesias (GID). The reasons for, and
the mechanism behind, the development of GID post transplantation
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patients transplanted prior to the placebo controlled trials, albeit to a
much less severe extent [71]. These GID are different in nature to the
typical dyskinesias seen in drug treated PD [72,73]. The severity of the
GID does tend to correlate negatively with the preoperative putaminal
F-dopa uptake but does not correlate with improvement in the ‘off’
UPDRS motor scores or daily dopaminergic medication level.
Furthermore their development does not seem to be related to the
severity of the pretransplant L-dopa induced dyskinesias (LID) or the
change in LID post operatively. In fact some transplant patients
showed an improvement in LID together with worsening GID [57,71].
Several possible factors may relate to the mechanism of these GID.
These include the relatively inhomogeneous graft mediated dopami-
nergic reinnervation of the host putamen [64], an effect from cells
other than the A9 dopaminergic neurones within the graft [74,75], in
particular the 5HT neurons included in the transplants [76,77] and the
graft size and placement within the striatum [78,79].
At the present time there is no clear consensus as to whether one,
or all, of these factors contribute. As a consequence of all these
possible confounds, a re-evaluation of the ﬁeld of neural grafting in PD
is being undertaken— a point that has perhaps been reinforced by the
recent long term post-mortem studies of FVM transplant patients
showing alpha-synuclein pathology in the graft [80–82].
In the ﬁrst of these studies, Mendez et al. [80] reported on 5
patients (referred to as subjects 1, 2, 4, 5 and 6) aged 55–69, with a
11–19 year history of PD, who underwent unilateral (subject 5) or
bilateral (subjects 1, 2, 4 and 6) transplantation of VM cell suspensions
from between two and four 6–10 week old fetuses into the putamen
(caudate and substantia nigra as well in subject 2). Immunosuppre-
ssion with cyclosporine covered the period 2 weeks prior to and
6 months following transplantation. Subjects 1 and 2 showed striking
clinical beneﬁts up to 3 years post transplant, with PET imaging
showing increased F-dopa uptake within the right striatum [83]. They
died of unrelated causes 3–4 years post transplantation and post-
mortem showed ∼98,913–202,933 grafted TH+ cells per side [83].
Subjects 4, 5 and 6 were reported to show variable clinical beneﬁt
lasting anywhere between 2 months and 3 years post transplantation.
Postmortem studies done 9–14 years post transplantation showed
well integrated grafts with between 9861 and 21,552 TH+ neurons
per putamen, mainly in the graft periphery. TH, alpha-synuclein and
ubiquitin staining for Lewy bodies showed their presence in the cell
bodies and terminals of the substantia nigra, the upper raphe nucleus,
neocortex and putamen, as one would expect in PD, but not in the
grafted dopaminergic neurons in the putamen. In addition, surround-
ing the grafts, there was a slightly higher density of CD45+microglia,
compared to a control PD putamen, but they were mostly in a non-
activated state.
In contrast, Kordower et al. reported on a 61-year-old patient with
a 22 year history of PD who had received bilateral solid FVM
transplants to the putamen from four, 6.5–9 week old, embryos [81].
The patient improved clinically for a period of ∼11 years and then
gradually deteriorated. Post mortem analysis at death 14 years post
transplant showed good graft survival with extensive TH innervation
of the host striatum. Staining for other markers of dopaminergic
neurons — vesicular monoamine transporter 2 (VMAT2) and
dopamine transporter (DAT) showed good staining for the former,
but very light to no staining for the latter, which diverges from
previous ﬁndings [60]. There was, as expected, a considerable loss of
TH neurons in the host nigra and those remaining contained both
cytoplasmic and aggregated alpha-synuclein and ubiquitin. The
unexpected ﬁnding was the presence of cytoplasmic, aggregated and
neuritic alpha-synuclein in grafted neurons. In other words, ubiqui-
nated aggregates, somewith the appearance of Lewy bodies were seen
in grafted neurons and the transplants were also ﬁlled with activated
microglia to a level far greater than that seen in the host striatum. Two
further brains were examined from patients who had undergone asimilar fetal transplant procedure and died approximately 4 years post
transplant and again showed cytoplasmic and nonaggregated alpha-
synuclein staining in the grafts [81]. This is at variance with what you
would expect, as transplanted neurons would developmentally be
only 4–14 years old and studies in normal humans have shown that
cytoplasmic (nonaggregated) alpha-synuclein is not seen in nigral
neurons until at least middle age and that aggregated alpha-synuclein
may even be absent in people over 100 years of age [84].
A further report by Li et al. also tends to support these ﬁndings
[82]. In their study two patients age 53 and 45, with a 16 and 7 year
history of PD underwent bilateral sequential transplantation of
dissociated FVM tissue from 6 to 8 week old aborted embryos into
either the putamen only or both caudate and putamen. The two
patients received immunosuppression with prednisolone and cyclos-
porine for 24 and 18 months and azathioprine for 20 and 6 months
respectively. They showed minimal clinical improvement [85] and at
post mortem 11–16 years post grafting, they had few surviving and
integrated grafted TH neurons (12,100–29,500 per injection track). In
both patients the grafted neurons again contained alpha-synuclein-
and ubiquitin-positive Lewy bodies and Lewy neurites, morphologi-
cally indistinguishable from those seen in surviving neurons in the
host substantia nigra pars compacta. In one patient who had received
sequential grafts to the putamen, the proportion of TH neurons with
detectable amounts of alpha-synuclein was 40% in the graft done
12 years ago, and 80% in the graft done 16 years ago, suggesting
evolving pathology with time. Finally in this paper, it was shown that
the Lewy bodies in the grafts also stained with an antibody to alpha-
synuclein phosphorylated at Ser129, indicating disease-related, post-
translationally modiﬁed and aggregated alpha-synuclein [86] and
while microglia accumulated around the grafts, they did not show
signiﬁcant activation.
These unexpected ﬁndings of Lewy body-like pathology in
implanted neurons in some patients with PD suggests that the
pathological process in Parkinson's disease can affect young dopami-
nergic cells, with implications to the ﬁeld of neural grafting in PD. It
remains unclear, though, how signiﬁcant these ﬁndings are to the
future use of cell therapies in PD as it would appear that not all cases
have developed this pathology and in those where it has been seen, it
is still only in a small proportion of cells and with an uncertain
signiﬁcance to the viability and efﬁcacy of the graft.
4. Xenografts
4.1. Porcine ventral mesencephalic cells
Xenografting involves the transplanting of tissue between species
and embryonic pig neural tissue has long been considered the most
suitable source for transplantation into human brains due to their ease
of breeding, the similarity in brain size between the species and the
potential for genetic modiﬁcation of porcine tissue. Early work on
xenotransplants demonstrated longer axonal and dendritic out-
growths from xenografted cells [87–90] and greater migration [91]
than equivalent allografted cells, which suggested that xenografts may
have some primary advantage over allografts in terms of their ability
to target diffuse pathology and recreate neural circuits. However it is
more likely that these differences relate to their different gestational
periods and the size of axonal projection required in bigger brains.
Nevertheless the ability of xenografted VM tissue to survive and
mediate functional beneﬁts in animal models of PD led onto a small-
scale clinical study. In this study by Schumacher et al. [92] 12 PD
patients had unilateral striatal transplants of suspensions of porcine
VM tissue (E25–E28 gestation). A signiﬁcant decrease, on average 19%,
in the UPDRS scores was reported, but there was no signiﬁcant
increase in F-dopa uptake at the transplant sites and a post-mortem
study ∼7.5 months post transplantation showed that only 638 TH+
cells out of ∼12 million transplanted porcine-derived cells survived at
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graft despite the patient being immunosuppressed with cyclosporine
A [93].
A second placebo controlled clinical trial involving 18 patients has
shown only modest improvements (20–25% on UPDRS) in both
transplant and sham surgery groups (Genzyme Press Release 16th
March 2001 [235]).
These studies have shown disappointing results and this limits the
enthusiasm for their adoption clinically, especially as the use of
xenogenic tissue for cell replacement therapy in PD will always need
to deal with some additional issues compared to allografts. Firstly
there are the problems of increased graft rejection and secondly there
are major issues regarding the potential transmission of porcine
endogenous retroviruses to the patient, which may yield some
hitherto undescribed new disease (reviewed in [70]). Thus, further
workwill be required before a decision can bemade as towhether this
tissue has any clinical potential.
5. Stem cells
Cells that can self renew and produce progeny as well as
differentiate are known as stem cells and various types of these cells
have been identiﬁed in a number of sites in organisms at different
stages of development. They have been considered prime candidates
for transplantation therapies for a range of diseases including PD due
to this proliferative capacity and the ease with which they can be
manipulated in vitro.
The principal goals for any stem cell-based cell replacement
therapy in PD include the development of xenogenic free culture
protocols that can generate large numbers of relatively deﬁned
transplantable cells; adequate survival and functional efﬁcacy from
the grafted cells following transplantation; the avoidance of potential
adverse effects of stem cell derived grafts, such as tumour formation
and immune rejection [94].
Several types of stem cell have been investigated in this respect and
include embryonic stem cells (ESCs), neural precursor cells (NPCs),
mesenchymal stem cells (MSCs) andmore recently induced pluripotent
cells (iPS cells), each of which will be discussed further in this review.
5.1. Stem cell derived allografts
5.1.1. Embryonic stem cells
Embryonic stem cells (ESCs) are extracted from the blastocyst and
have the potential to self renew and differentiate into all the cells of an
organism. Following the initial isolation of ESCs from the inner cell
mass of themouse blastocyst in 1981 [95,96], the ﬁrst reported human
ESC line was established by Thomson et al. in 1998 [97].
In relation to PD, much work has been devoted to the potential use
of ESCs as a source of dopaminergic cell replacement and several
methods have been explored to try and persuade ESCs to adopt this
phenotype. The development of dopaminergic neurons from embryo-
nic stem cells is a complex process involving a number of stages both
in vivo and in vitro, including the formation of neural stem cells, and
the precise mechanisms involved are not fully understood [98–101].
Mouse ESCs have been cultured and transplanted directly into the
mouse striatum, leading to some dopaminergic differentiation and
evidence of functional recovery, but the formation of teratomas from
remaining undifferentiated stem cells was also noted in a signiﬁcant
number of animals [102]. The differentiation of mouse ESCs into
Neural Precursor Cells (NPCs) (neural stem cells that can only go on to
differentiate into neurons, oligodendrocytes and astrocytes) has been
achieved [103,104]. Mouse ESC derived neural stem cells cultured with
ﬁbroblast growth factor-2 (FGF-2) and epidermal growth factor (EGF)
can also undergo prolonged expansion and still differentiate into
neurons and astrocytes on sequential growth factor withdrawal in
vitro and following transplantation into the mouse brain in vivo [105].Human ESCs have now been shown to have similar properties in vitro.
However, the number of tyrosine hydroxylase positive (TH+) neurons
(which indicate a catecholaminergic- and so includes dopaminergic-]
phenotype) resulting from these methods has, though, been dis-
appointingly low (b1%) [106,107].
Attempts to further increase the differentiation of dopaminergic
neurons from ESCs in vitro have involved several different
approaches. One method involves co-culturing ESCs with feeder
cells that possess stromal cell derived inducing activity (SDIA). Mouse
ESCs grown with mouse PA6 stromal cells have produced approxi-
mately 16% TH+ neurons in one week [108], while ∼7% of the total
cells in similar human ESC cultures have given rise to a TH+
phenotype [109,110]. However, the molecules involved and the
mechanism by which the stromal feeder cells produce this differ-
entiation is not yet known.
Other empirical studies have tried a number of soluble growth
factors and chemicals to induce the dopaminergic neuronal differentia-
tion of mouse [111], primate [112] and human ESCs [99,101,113–115].
Some groups have combined this strategy with mouse stromal cell
co-culture (mESCs — [116]; hESCs — [117–119]), while Roy et al. have
grown human ESCs with human fetal midbrain astrocytes in
addition to the use of growth factors [120]. Genetic manipulation
has also been used as a way to increase the formation of dopamine
neurons from ESCs including transcription factors such as Nurr1,
Lmx1a, Pitx3 which have roles in the normal differentiation of
dopamine neurones during development [121–123]. In all cases one
of the major challenges has been to produce appropriate dopami-
nergic cells from an ES cell source without using any non-human
reagents, as clearly the use of such products will create problems, if
and when, the treatment comes to clinical use. In addition as with
all therapies derived from such a source, a stable karyotype needs to
be shown within the cell lines and their progeny if they are to gain
acceptance for clinical use.
These above methods have produced varying proportions of TH+
neurons, with the best results involving dopaminergic differentiation
from mouse ESCs using a combination of feeder cell culture, growth
factors and genetic manipulation. With this, up to 90% of the
neuronally differentiated β-III tubulin positive (TuJ+) cells developed
a TH+ phenotype [124]. With human ESC, the most successful
differentiation protocols have, until now, generally involved feeder
cell cultures with the addition of growth factors and this produces TH
+/neuronal TuJ+ proportions of between 60 and 75% [113,117,120].
Recently though, Cho et al. have developed a protocol which involves
the formation of embryoid bodies (aggregates of ESCs formed by
using culture methods that prevent the adhesion of cells to a surface
and thus formation of the typical colony growth), followed by neural
precursor cell selection and culture producing ∼86% TH+ neurons/
TuJ+ cells. Of these TH+ cells, the majority expressed the markers of
true midbrain dopamine neurons [125]. This is important as it is
becoming increasingly clear that the best dopaminergic cells for
treating PD will be those that are truly of nigral origin.
Many of the studies above have gone on to examine ESC derived
TH+ cell survival and functional efﬁcacy following transplantation
into animal models of PD. Dopaminergic rich transplants derived
from mouse ESCs have generally survived and produced beha-
vioural recovery following grafting into the 6-OHDA lesioned rat
model of PD [108,124]. Primate ESC derived dopaminergic neuronal
rich grafts transplanted into the putamen of the MPTP treated
primate PD model have also shown survival of grafted TH+ neurons
with signiﬁcant neurological recovery and increased F-dopa uptake
on functional imaging [112]. However studies using dopaminergic
cells derived from human ESC have been more disappointing with
only limited functional recovery and then only in those animals
with large numbers of surviving TH+ neurons in the graft. (∼1300
per graft [115]; ∼10,732 per graft [125]; 27,000 TH+ cells/mm3
[120]).
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of human ESC derived dopaminergic cell rich grafts in animal models
of PD. Theremay be increased cell death due to the relativematurity of
the neurons so derived from cells which have been grown in culture
for relatively long periods of time. There may also be unstable TH
expression in transplants [94,125,126]. Additionally, there have been
concerns about the mode of action of the grafts in producing
functional beneﬁts, with the possibility of non-speciﬁc mass lesion
effects from implanting relatively large numbers of proliferating TH+
cells [120,127].
Apart from the issues of differentiation, the future potential of ESCs
as a source for cell replacement therapy in PDwill critically depend on
avoiding adverse effects such as tumour formation and immune
rejection. ESC transplants have been known to give rise to tumours,
including teratomas composed of cells from all 3 germ cell layers,
following implantation into animal models of disease including PD
[102,128]. The in vitro differentiation of ESCs prior to transplantation
has been shown to reduce the incidence of tumour formation
following grafting [110], but extensive differentiation and maturation
may also adversely affect the survival of grafted cells. In addition the
recent study of Roy et al. in 2006 suggested that pre-differentiating
ESCs to a neuronal lineage still does not remove forebrain progenitor
cells, which continue to proliferate post transplantation with possible
adverse effects [120]. Thus, blocking cell proliferation and survival
pathways by manipulation of relevant genes may also be an effective
way of reducing the chance of tumour formation [129], but it is
currently not known if this is possible. Other strategies have involved
genetic manipulation to make undifferentiated, dividing ESCs more
susceptible to antimicrobial substances (eg: insertion of ‘suicide
genes’ under the control of tetracycline or gancyclovir) [103,130,131];
improved sorting of ESCs using inserted ﬂuorescent reporter genes
and ﬂuorescent activated cell sorting (FACS) [132]; the use of
conjugated cell-surface antibodies to allow for magnetic activated
cell sorting (MACS) [133]; and ﬁnally the use of pharmacological
agents that target dividing cells [134].
Overall, although human ESCs have much potential for use as a
source of dopaminergic cells for grafting in PD, more work is needed
to ensure that it can be done efﬁciently and safely with the pro-
duction and survival of large numbers of true nigral neurons. In
addition, it will be essential to optimise the production of such cells
and improve their survival and functional capacity following trans-
plantation while avoiding potential adverse effects, before clinical
trials are attempted.
5.1.2. Neural precursor cells
A neural precursor cell (NPC) is a type of stem cell which is
committed to the neural lineage and can generally only form neurons,
oligodendrocytes or astrocytes, although some have proposed that
they may be more multipotent than this [135]. They can be found in
embryonic and adult neural tissue and also derived from ESC, as
described above.
5.1.2.1. Fetal-derived neural precursor cells. Neural precursor cells
(NPCs) have been isolated from a number of sites in the fetal animal
and human brain including the mesencephalon [136–141]. In relation
to PD, similar principles to those involved in developing ESC derived
transplants have been behind the studies on NPCs as a cell source for
transplantation [142,143].
In terms of proliferation and differentiation, fetal NPCs from all
parts of the central nervous system have been found to proliferate in
vitro in the presence of growth factors such as basic FGF and EGF
[139,144] and even following prolonged expansion in vitro they seem
to retain some of their original regional properties. Thus, dopaminer-
gic differentiation is increased in NPCs from ventral mesencephalon
(VM) compared to NPCs derived from other regions of the brain
[145,146].A number of studies have now explicitly explored the formation of
dopamine neurons from NPCs beginning with the study in 1998 by
Studer et al. This study demonstrated that NPCs from the rat VM could
be grown in vitro, with expansion using bFGF and then differentiated
to yield a signiﬁcant number of TH+neurons, with functional beneﬁts
on transplantation in rat PD models [142]. The proportion of TH+
neurons produced using this approach could be further increased by
culturing the cells in low oxygen conditions [147]. Others have also
demonstrated the formation of TH+ neurons from embryonic rodent
mesencephalon-derived NPCs, with behavioural recovery on trans-
plantation in rat models of PD [148–150].
Carvey et al. have produced a proportion of 20–25% TH+ cells from
rat embryonic mesencephalon neural progenitors using added soluble
factors such as interleukin-1 (IL-1), IL-11, leukaemia inhibitory factor
(LIF) and glial cell-line derived neurotrophic factor (GDNF). Further
proliferation of these TH+ cells produced clones, but now with up to
98% of the cells showing a TH+ phenotype, and subsequent
transplantation into rat models of PD resulted in signiﬁcant functional
recovery [151].
Genetic modiﬁcation of rat forebrain NPCs to produce factors
involved in dopaminergic speciﬁcation and survival (Nurr1, sonic
hedgehog (SHH) and Bcl-XL;Nurr1 and Mash1 or Pitx3) has been
shown to result in dopaminergic differentiation and functional beneﬁt
on grafting in 6-OHDA rats [152,153]. Overexpression of Nurr1 in rat
NPCs resulted in ∼5% TH+ expression [154], while co-expression of
Nurr1 and Neurogenin2 (a transcription factor required for the correct
development of mesencephalic dopamine neurons), resulted in the
increased maturation of the midbrain dopaminergic phenotype [155].
In contrast, Roybon et al. did not ﬁnd an increased formation of
dopaminergic neurons following retroviral vector-induced transduc-
tion of rat embryonic NPCs with the midbrain transcription factors
Lmx1a, Msx1, neurogenin2 and Pitx3 [156,157]. In all cases the
survival of TH+neurons following transplantation has been poor with
rates of only 0.8–4.3% [142,150].
Initial studies involving NPCs obtained from the human fetal
mesencephalon involved expansion in FGF and EGF but the number of
dopaminergic neurons derived from such an approach was very low
(b0.01%) and this was also seen following transplantation in rat PD
models [158]. Subsequently, Storch et al. showed expansion of
mesencephalic human NPCs under low oxygen conditions with
further induction of differentiation by interleukin-1α (IL-1α), LIF,
IL-11 and GDNF resulting in ∼1% TH+neurons [159]. Others have used
a different combination of factors with some possible functional
beneﬁts [160], andWang et al. conﬁrmed increased functional efﬁcacy
of transplantation of pre-differentiated (26% TH+) versus non-
differentiated (1.4% TH+) mesencephalon-derived NPCs [161]. Riaz
et al. managed to improve on this using a combination of brain derived
neurotrophic factor (BDNF), dopamine and forskolin with either
retinoic acid or GDNF [162], while Yang et al. and Christopherson et al.
only managed to obtain 25% and 4–10% TH+ neurons using a
combination of different factors. They also found very few surviving
TH+ cells following transplantation into the striatum of 6-OHDA
lesioned rats and it was unclear if this was due to loss of TH expression
or preferential death of TH+ neurons [163,164]. Liste et al. have since
shown enhanced generation of dopaminergic neurons from human
NPCs by immortalisation and overexpression of the anti-apoptotic
protein Bcl-XL in vitro and in vivo [165,166].
Despite the presence of some continued cell division, the
development of tumours from NPC derived grafts has not been
reported and this decreased tumorigenic potential is of obvious
advantage compared to the approach of generating dopaminergic cells
from an ESC source. However ethical and practical limitations with
NPC extraction and differentiation still remain as the cells need to be
derived from aborted fetuses and it is still not clear when this should
be done in terms of the optimal age for harvesting. Further work is also
needed to produce an efﬁcient protocol for the generation of large
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with this source of cells can be considered.
5.2. Stem cell derived autografts
5.2.1. Endogenous adult neural precursor cells
The discovery of evidence for the presence of dividing cells in the
adult rat hippocampus by Altman and Das in 1965 suggested that
endogenous neural stem cells and neurogenesis in the adult
mammalian central nervous system may occur [167]. However it
was not until 1992, when such cells were isolated from the adult
mouse striatumwith subsequent in vitro proliferation and differentia-
tion into neurons and astrocytes, that the ﬁeld really took off [168].
Subsequently, in vivo neurogenesis and the isolation of neural
precursor cells has now been convincingly demonstrated in the
adult subventricular zone (SVZ) [169,170] and the subgranular zone of
the hippocampal dentate gyrus [171–174]. However several other
regions of the adult central nervous system have been shown to
possess self-renewing cells which can be isolated, expanded and
differentiated in vitro, including the cerebral cortex [175], hypotha-
lamus [176], septum [172], optic nerve [175], retina [177] spinal cord
[178] and more controversially the adult substantia nigra [179]. NPCs,
including those with neurogenic and dopaminergic potential, have
been isolated from the adult substantia nigra/tegmentum by some
groups [180,181] and Zhao et al. have even suggested that the
presence of a stable number of dopaminergic neurons in the adult
rodent substantia nigra despite continuing neurodegeneration indi-
cates that there is a degree of neurogenesis throughout the lifetime of
the animal — a process that can be up-regulated following
dopaminergic (MPTP) lesions [182]. Others have conﬁrmed this
using nestin-Lac-Z transgenic mice [183], while some other studies
have not shown this to occur [184].
Any neurogenesis present in the adult substantia nigra may be
inﬂuenced by variables such as the level of local growth factors (e.g.
GDNF, BDNF and Platelet derived growth factor (PDGF)) all of which
may be low in the midbrain and especially in PD [185,186], as well as
physiological stimuli like exercise and environmental enrichment
[187]. In addition, dopamine and dopamine agonists have been shown
to inﬂuence neurogenesis in the subependymal and subgranular
zones of the adult rodent brain [69,188,189] and further investigation
of these factors may be of signiﬁcance for PD.
The presence of NPCs in the adult brain has also generated the
possibility of ex-vivo autologous transplantation for PD. Despite the
limited evidence from animal studies, there has been only one
recorded attempt of autologous transplantation of adult neural
precursor cells in a patient with PD (in [70]). The patient had a
cerebral cortical biopsy, from which NPCs were isolated. These were
“expanded” in vitro for months with several ‘epigenetic factors’
resulting in the formation of neurons, of which 15% were dopaminer-
gic. These cells were then transplanted into the patient's left putamen
and functional assessment showed an ∼88% improvement in the
motor ‘off’ phase at 12 months, with F-dopa PET showing a 55.6%
increase in left putaminal dopamine uptake. However, this case has
never been fully published and much more work with animal models,
along with a better understanding on the natural functions, develop-
ment and differentiation of adult NPC is needed before future clinical
trials using this approach can be considered.
5.2.2. Carotid body stem cells
In 2007, Pardal et al. reported on the discovery of a resident
population of neural-crest-derived progenitors in the carotid body of
adult mice [190]. These stem cells are activated by hypoxic conditions
and divide and give rise to new neuron-like dopaminergic glomus
cells. They also provided evidence that these progenitors are the glia-
like type II sustentacular cells of the carotid body, which can
proliferate and differentiate in vitro and produce GDNF.Following the experience with carotid body tissue as a possible
source for cell replacement therapy in PD (see above), the potential to
now use these carotid body stem cells in a similar way may enable the
ex vivo generation of large numbers of dopaminergic glomus cells for
autologous transplantation.
5.2.3. Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are non-haematopoietic,
multipotent cells which arise from the stromal structures of the
bone marrow and are present in adults [191]. In vivo, they usually
give rise to osteocytes, chondrocytes and adipocytes, but may have
the potential for transdifferentiation to form other non-mesench-
ymal cell types, including neurons [192,193]. MSCs with neurogenic
potential have also been found in peripheral blood and thus they
represent a potentially very accessible source of cells for auto-
logous transplantation therapies in neurodegenerative disease,
including PD.
MSCs have been isolated from both rat and human bone marrow
using cell surface markers and efﬁciently differentiated into dopami-
nergic neurons using deﬁned protocols involving gene transfection
and growth factors such as bFGF, forskolin, ciliary neurotrophic factor,
and GDNF [194]. Using this approach up to 41% of the 96.5% neuronal
type cells so derived have a TH+ phenotype and on transplantation
into a rat model of PD, they demonstrated migration, dopamine
secretion and functional recovery. Despite these positive ﬁndings,
there is some uncertainty regarding their true in vivo differentiation
potential [195,196] and the mechanism of action of these cells post
implantation [197,198], which will need to be resolved before they can
be considered for clinical use.
5.2.4. Induced pluripotent stem cells
Of all the types of stem cell considered above, ESCs have been
regarded to possess the most potential as an efﬁcient, standardised
source for cell replacement therapies in the future treatment of PD.
However, ethical and practical issues such as the need to use human
embryos and the possibility of immune rejection will continue to
limit development in this area. Therefore, the recent attempts to
form pluripotent/ESC-like cells from adult somatic cells, involving
the reprogramming of the somatic cell nucleus, have been very
exciting with major implications given the beneﬁts such autografts
will offer.
In somatic cell nuclear transfer, an unfertilised oocyte has its
nucleus removed and the nucleus of an adult somatic cell is inserted
instead, resulting in a pluripotent cell which can develop into a cloned
embryo and animal (the method used to produce Dolly the sheep)
[199]. Another method involves the fusion of an adult somatic cell
with an ESC to form a pluripotent cell [200,201]. However, these
methods still require the use of human embryos or oocytes, with the
accompanying problems.
Thus, the ability to reprogram adult cells has been an active
area of research and recently Takahashi and Yamanaka showed
that ESC like cells could be derived from embryonic and adult
mouse ﬁbroblasts through the over expression of four transcription
factors — Oct3/4, Sox2, c-Myc and Klf4, using retroviral vectors
[202]. These cells were named induced pluripotent stem cells (iPS
cells) and while they showed several properties of ESCs such as the
formation of embryoid bodies in vitro and teratomas in vivo and
differentiation into various distinct cell types, some features such as
gene expression, epigenetic status and contribution to developmen-
tal stages of the organismwere similar, but not identical to ESC [203].
Several subsequent studies have used different selection methods for
the induced ESC-like state and produced mouse iPS cells which are
more indistinguishable from ESC [204–207]. In addition, iPS cells
have been formed from other forms of somatic cell such as mature B
lymphocytes [208] as well as adult mouse hepatocytes and gastric
epithelial cells [209].
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Yamanaka's group then reported on the generation of iPS cells from
adult human dermal ﬁbroblasts using the same four factors as had
been shown to work with mouse cells [210]. It involved introducing a
mouse retroviral receptor to improve transduction efﬁciency of the
retroviral vectors and culturing with bFGF under primate ESC culture
conditions, with the morphological identiﬁcation and mechanical
isolation of human ESC-like colonies at day 30, followed by expansion
on feeder cells. The similarity of these human iPS cells to human ESC
was evident using cell surface-marker expression, epigenetic status,
telomerase activity, in vitro embryoid body formation, directed
differentiation into neural and cardiac cells and teratoma formation
in vivo [210]. Other groups have similarly demonstrated the formation
of iPS cells from human ESC-derived somatic cells or human neonatal
ﬁbroblasts using the same combination of Oct3/4, Sox2, c-Myc and
Klf4 [211,212], while Yu et al. have used Oct4, Sox2, Nanog and Lin28 to
reprogram their ESC-derived somatic cells [213].
Thus, once derived, iPS cells could be used in a similar manner to
ESC in the development of cell replacement therapies for degenerative
disease and initial steps in the use of this technology for PD have now
been taken by Wernig et al. [214]. Mouse ﬁbroblast derived iPS cells
expanded on irradiated mouse embryonic ﬁbroblast feeder cells
formed spheroid embryoid bodies in nonadherent cultures and then
clusters of neuroepithelial-like cells in serum-free media. These cells
were isolated and propagated with FGF-2 and expressed the neural
stem cell markers nestin, Sox2 and Brn2. On treatment with SHH and
FGF8, followed by withdrawal of all factors, most cells developed a
neuronal morphology and were β-III-tubulin+ (TuJ+), with up to 5%
of these TuJ+ cells also showing TH+ immunoreactivity. A majority of
the TH+ cells also expressed En1, Pitx3 and Nurr1, factors typically
seen in midbrain dopamine neurons. They then took ∼100,000–
300,000 of the differentiated cells obtained following growth factor
withdrawal and transplanted them into the striatum of 6-OHDA
lesioned rats. This resulted in behavioural recovery of 4/5 rats at 4
weeks, with histological analysis showing ∼29,000 TH+ cells in one of
the recovered rats and only ∼1500 TH+ cells in the centre of the graft
in the non-responding animal, with little ﬁbre extension into the
adjacent striatum. Of concern, in the recovered animals the trans-
plants continued to show evidence of cell proliferation and teratoma
formation. However, using FACS to separate out the remaining
pluripotent cells prior to grafting resulted in similar behavioural
recovery with smaller grafts and importantly no evidence of tumour
formation at 8 weeks [214].
Despite the obvious potential for iPS cell based therapies for PD
and other diseases, there are several issues which will need to be
resolved before their clinical use can be considered. In general, the
efﬁciency of generation of iPS cells has been relatively poor, ∼4–125
ESC-like colonies from ∼800,000 mouse embryonic ﬁbroblasts [205]
and ∼10 iPS colonies from ∼50,000 human adult ﬁbroblasts [210].
Park et al. [211]also found that postnatal or adult human ﬁbroblasts
displayed a much lower efﬁciency of reprogramming compared to
fetal or ESC-derived ﬁbroblasts (0 versus 39–118 ESC-like colonies
from 100,000 somatic cells), even following supplementation with
genes known to have a role in establishing human cells in culture –
hTERT and SV40 large T [215,216] – (7–21 versus ∼250 ESC-like
colonies from ∼100,000 somatic cells). Thus, further methods are
being explored to increase the efﬁciency of iPS cell formation.
In this respect, the observed enhancing activity of SV40 large T
antigen, which has potent anti-apoptotic activity, has also been
demonstrated by Mali et al. (23–70 fold increase in reprogramming)
[217]. In addition, combining the factors used in Takahashi et al. [210]
and Yu et al. [213] has produced a ∼10 fold increase in iPS cell
formation from human foreskin ﬁbroblasts [218] compared to using
only the 4 factors of study of Yu et al. Furthermore, Mikkelsen et al.
have suggested that the incomplete repression of lineage-specifying
transcription factors and inefﬁcient DNA de-methylation may causesome cells to be trapped in a partially reprogrammed state and that
RNA inhibition of transcription factors and DNA methyltransferase
inhibitors can lead to more efﬁcient reprogramming towards the iPS
cell state [219].
The current protocols for the generation of iPS cells involve genetic
manipulation, viral vectors and animal derived culture conditions,
which would prevent them from being used clinically. However, Shi
et al. have recently reported on the formation of iPS cells from mouse
ESC-derived neural progenitor cells with fewer genetic manipulations
(viral transduction of only Oct3/4 and Klf4) but with the addition of
other small molecules (BIX-01294, an inhibitor of the G9a histone
methyltransferase). They found using this approach that the efﬁciency
and characteristics of the iPS cells were similar to those generated
with the four factors [220].
iPS cell derived grafts also pose an increased risk of tumour
formation as with ESC derived grafts, which can be decreased by
preselecting the more differentiated cells prior to grafting [214].
However the reactivation of the viral induced oncogene c-myc has
been shown to increase tumorigenicity in germ-line competent
chimeras formed using iPS cells [205]. So importantly, the study of
Nakagawa et al. showed that iPS cells can be generated from human
adult ﬁbroblasts without c-myc, albeit at a slower rate, with no
tumours developing in chimeric mice generated from these iPS cells in
a follow up study period of ∼3–4 months [221].
This rapidly developing ﬁeld of stem cell biology has much
potential for the development of patient speciﬁc cell replacement
therapies for PD, without the ethical and practical problems found
with stem cells of embryonic or fetal origin. However, many
challenges will have to be overcome in terms of minimising the
genetic and viral manipulation required to form iPS cell derived
dopaminergic neurons, as well as avoiding animal derivatives in their
culturing. In addition, improving the efﬁciency and quality of the
induction and subsequent differentiation processes and reducing
tumour formation are all necessary for this approach to be useful in
clinical practice. Finally ensuring that stem cells derived from patients
have not ‘inherited’ the problem of the disease itself will be an
important issue, so as to ensure that any grafts derived from such a
source do not succumb to the disease process in the short term.
6. Conclusion
The development of deﬁnitive treatments for Parkinson's disease
will ultimately rely on further understanding the precise pathogenic
mechanisms of the disease. However, until such disease modifying
treatments are available, efforts will continue in the development of
strategieswhich can help patients by relieving symptoms and possibly
retarding the progression of the disease. In this respect, better
deﬁning disease heterogeneity will be important, as each novel
treatment may be more suitable for only some types of PD patients.
Cell replacement therapies for Parkinson's disease have had a
variable history with a number of different cell sources being explored
in experimental studies using animal models of disease as well as in
patients. The early clinical experience with FVM transplants demon-
strated that some patients obtained signiﬁcant beneﬁts with this
treatment, but this was not seen in the larger double blind placebo
controlled trials possibly due to a combination of factors relating to
patient selection, the amount and mode of tissue engraftment, the
power and design of the studies and the level of immunosuppression.
While many of these issues can potentially be addressed experimen-
tally, there will always be practical and ethical issues with the use of
FVM tissue as a transplant source.
Thus, the search for new cell sources for transplantation in PD has
gained much momentum especially with the recent work in the stem
cell ﬁeld. While ESCs have shown the most potential, the recently
developed induced pluripotent stem cells bring the very real prospect
of patient speciﬁc cell replacement therapies. Still, there are many
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trialled clinically and this may only be possible once a further
successful FVM trial has been completed. Indeed, at the present time
FVM tissue still remains the best standard against which to test future
sources of cells for dopaminergic cell replacement in PD. However, it
should be stressed that the success of the approach using cell
therapies in PDwill be through incremental advances and even then it
will only ever treat those problems in PD that relate to a loss of striatal
dopamine. For cures, we are going to have to better understand
pathogenesis and in that respect iPS cells may be very instructive in a
completely different way, namely through their ability to model
disease.
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